Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: A systematic review and meta-analysis
Jiawen Deng, Daniel Rayner, Harikrishnaa Ba Ramaraju, Umaima Abbas, Cristian Garcia, Kiyan Heybati, Fangwen Zhou, Emma Huang, Ye-Jean Park, Myron Moskalyk
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.01.010
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Lastly, we found that fluvoxamine was not associated with reduced hospitalization once we excluded one study with a high risk of bias rating. This was likely due to loss of precision from a reduced sample size given the small number of studies and patients included in this review. The incorporation of larger, betterdesigned RCTs in future meta-analyses can help confirm our findings relating to hospitalization.
CONCLUSION This systematic review and meta-analysis of 6 RCTs and 5 observational studies found that fluvoxamine may reduce mortality and hospitalization based on moderate quality of evidence. Medium
J o u r n a l P r e -p r o o f
CONFLICT OF INTEREST The authors declare no conflicts of interest.
J o u r n a l P r e -p r o o f
GRADE Working Group quality of evidence rating [28] High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect a The risk in the intervention group (and its 95% CI) is based on the assumed risk in..
References
Bloch, Mcguire, Landeros-Weisenberger, Leckman, Pittenger, Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder, Mol Psychiatry,
doi:10.1038/mp.2009.50Bollini, Pampallona, Tibaldi, Kupelnick, Munizza, Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials, Br J Psychiatry,
doi:10.1192/bjp.174.4.297Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Calusic, Marcec, Luksa, Jurkovic, Kovac et al., Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls, Br J Clin Pharmacol,
doi:10.1111/bcp.15126Cheng, Pullenayegum, Marshall, Iorio, Thabane, Impact of including or excluding botharmed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study, BMJ Open,
doi:10.1136/bmjopen-2015-010983Guo, Harari, Chernecki, Thorlund, Forrest, Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials, Am J Trop Med Hyg,
doi:10.4269/ajtmh.21-1310Guyatt, Oxman, Santesso, Helfand, Vist et al., GRADE guidelines: 12. J o u r n a l P r e -p r o o f Preparing summary of findings tables-binary outcomes, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2012.01.012Guyatt, Oxman, Vist, Kunz, Falck-Ytter et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ,
doi:10.1136/bmj.39489.470347.ADHashimoto, Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication, J Pharmacol Sci,
doi:10.1016/j.jphs.2014.11.010Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01231-xHoertel, Sánchez-Rico, Kornhuber, Gulbins, Reiersen et al., Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19, J Clin Med Res,
doi:10.3390/jcm11195882Ishikawa, Ishiwata, Ishii, Kimura, Sakata et al., High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503, Biol Psychiatry,
doi:10.1016/j.biopsych.2007.04.001Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Metaanalysis, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.6269Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2020.22760Mccarthy, Naggie, Boulware, Lindsell, Stewart et al., Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial,
doi:10.1101/2022.10.17.22281178v2Min, Kim, Oh, Kim, Lee, COVID-19 Prognosis in Association with Antidepressant Use, Pharmacopsychiatry,
doi:10.1055/a-1842-7859Nawas, Zeidan, Edwards, El-Desoky, Barriers to COVID-19 Vaccines and Strategies to Improve Acceptability and Uptake, J Pharm Pract,
doi:10.1177/08971900221081621Németh, Szûcs, Vitrai, Juhász, Németh et al., Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study, Ideggyogy Sz,
doi:10.18071/isz.74.0389Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.33090Page, Mckenzie, Bossuyt, Boutron, Hoffmann et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ,
doi:10.1136/bmj.n71Pepperrell, Ellis, Wang, Hill, Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19, Open Forum Infect Dis,
doi:10.1093/ofid/ofac174Puzhko, Aboushawareb, Kudrina, Schuster, Barnett et al., Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder, J Affect Disord,
doi:10.1016/j.jad.2020.01.113Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., r n a l P r e -p r o o f Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health,
doi:10.1016/S2214-109X(21)00448-4Ren, Lin, Lian, Zou, Chu, Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews, J Gen Intern Med,
doi:10.1007/s11606-019-04925-8Sattar, Valabhji, Obesity as a Risk Factor for Severe COVID-19: Summary of the Best Evidence and Implications for Health Care, Curr Obes Rep,
doi:10.1007/s13679-021-00448-8Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab050Seo, Kim, Bae, Park, Chung et al., Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial, Infect Chemother,
doi:10.3947/ic.2021.0142Sterne, Hernán, Reeves, Savović, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ,
doi:10.1136/bmj.i4919Sterne, Savović, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ,
doi:10.1136/bmj.l4898Sweeting, Sutton, Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Stat Med,
doi:10.1002/sim.1761
